- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02404194
Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis
December 1, 2022 updated by: Christine Hooker, Rush University Medical Center
Optimizing Cognitive Training to Improve Functional Outcome in Clinical High Risk (CHR)
This project is a randomized-controlled trial to test the efficacy of computer-based targeted cognitive training (TCT) versus a placebo intervention of commercial computer games in adolescent/young adults at clinical high risk (CHR) for psychosis.
TCT is designed to optimize learning-induced neuroplasticity in vulnerable neurocognitive systems.
A main aim is to test the hypothesis that this neuroscience-guided TCT intervention will improve neural function, and that these neural improvements will improve cognition and functional outcome.
CHR participants will be randomly assigned to 40 hours of TCT or placebo computer games completed within 10 weeks.
TCT consists of 20 hours of training in cognition, including processing speed, memory, attention, and cognitive control followed by 20 hours of training in social cognition including affect recognition and theory of mind.
Neuroimaging, cognition, social cognition, clinical symptoms, and functional status will be assessed at baseline, after 20 hours/5 weeks of cognitive training (mid-intervention), and after 20 hours/5 weeks of social-cognitive training (post-intervention).
Cognition, social cognition, symptoms, and functioning will also be assessed at a 9 month follow-up (i.e. 9 months after intervention completion).
We predict that TCT will lead to improvements in neurocognitive function and functional status.
The results of this study will provide important information about a benign, non-pharmacological intervention for improving cognition and functional outcome in CHR individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
139
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 30 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- English speaking
- One or more psychosis-risk syndromes as defined by the Structured Interview for Psychosis-Risk Syndromes (SIPS)
Exclusion Criteria:
- Intelligence Quotient (IQ) < 70
- Major medical illness or neurological disorder
- Lifetime history of Axis I psychotic disorder and/or clear evidence that psychosis-risk syndrome is due to non-schizophrenia-spectrum Axis I or Axis II disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Targeted Cognitive Training
40 hours of computerized cognitive training
|
Targeted Cognitive Training is performed on the computer through Posit Science.
Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks.
Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving.
After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
Other Names:
|
|
PLACEBO_COMPARATOR: Computer Games
40 hours of computer games
|
The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games.
These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery
Time Frame: Change in cognition from baseline (pre-intervention) to 10 weeks (post-intervention)
|
Behavioral assessment of cognition
|
Change in cognition from baseline (pre-intervention) to 10 weeks (post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Function: Social and Role Scales
Time Frame: Change in functioning from baseline (pre-intervention) to 10 weeks (post-intervention)
|
Behavioral assessment of daily functioning
|
Change in functioning from baseline (pre-intervention) to 10 weeks (post-intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine I Hooker, PhD, Rush University Medical Center, Dept of Psychiatry & Behavioral Sciences
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (ACTUAL)
November 23, 2020
Study Completion (ACTUAL)
February 15, 2021
Study Registration Dates
First Submitted
March 16, 2015
First Submitted That Met QC Criteria
March 26, 2015
First Posted (ESTIMATE)
March 31, 2015
Study Record Updates
Last Update Posted (ACTUAL)
December 2, 2022
Last Update Submitted That Met QC Criteria
December 1, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MH105246
- R01MH105246 (NIH)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical High Risk for Psychosis
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Monument Therapeutics LimitedNational Institute of Mental Health (NIMH); Foundation for the National Institutes... and other collaboratorsRecruitingClinical High Risk for Psychosis (CHR)United States
-
University of California, DavisSacramento County Behavioral Health ServicesRecruitingClinical High Risk for Psychosis | Ultra High Risk for PsychosisUnited States
-
Medical University of ViennaRecruitingClinical High Risk for Psychosis | Ultra-high Risk for Psychosis | At-risk Mental StateAustria
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
Centre Psychothérapique de NancyRecruitingClinical High Risk for Psychosis (CHR)France
-
University of ZurichUnknown
-
University of California, DavisCompletedPsychosis | Clinical High Risk for PsychosisUnited States
-
Centre for Addiction and Mental HealthUnknownClinical High Risk for PsychosisCanada
-
University of California, DavisGinger.ioCompletedPsychosis | Clinical High Risk for PsychosisUnited States
Clinical Trials on Targeted Cognitive Training
-
University of California, San FranciscoCompletedSchizophrenia | PsychosisUnited States
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruitingPTSD | Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Psychosis | Serious Mental IllnessUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedSchizophreniaUnited States
-
AdventHealthNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Disorder | ApathyUnited States
-
Massachusetts General HospitalDeborah Munroe Noonan Memorial Research FundCompleted
-
Massachusetts General HospitalLouis V. Gerstner III Research Scholar AwardCompletedTourette Syndrome | Attention-Deficit/Hyperactivity Disorder
-
University of ZurichUniversity Hospital, ZürichRecruitingParkinson's Disease | Mild Cognitive ImpairmentSwitzerland
-
National Institute of Mental Health (NIMH)CompletedSchizophreniaUnited States
-
Peking University First HospitalRecruiting
-
Peking University First HospitalCompleted